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2 
Abstract 34 
The identification of new markers for malignant pleural mesothelioma (MPM) is a 35 
challenging clinical need. Here, we propose a quantitative proteomics primary screen 36 
of the cell surface exposed MPM N-glycoproteins, which provide the basis for the 37 
development of new protein-based diagnostic assays. Using the antibody-independent 38 
mass-spectrometry based cell surface capturing (CSC) technology, we specifically 39 
investigated the N-glycosylated surfaceome of MPM towards the identification of 40 
protein-marker candidates discriminatory between MPM and lung adenocarcinoma 41 
(ADCA). Relative quantitative CSC analysis of MPM cell line ZL55 in comparison 42 
with ADCA cell line Calu-3 revealed a bird’s eye view of their respective 43 
surfaceomes. In a secondary screen of fifteen MPM and six ADCA, we used high 44 
throughput Low Density Microarrays (LDAs) to verify specificity and sensitivity of 45 
nineteen N-glycoproteins overregulated in the surfaceome of MPM. This proteo-46 
transcriptomic approach revealed thy-1/CD90 (THY1) and teneurin-2 (ODZ2) as 47 
protein-marker candidates for the discrimination of MPM from ADCA. Thy-1/CD90 48 
was further validated by immunohistochemistry on frozen tissue sections of MPM and 49 
ADCA samples. Together, we present a combined proteomic and transcriptomic 50 
approach enabling the relative quantitative identification and pre-clinical selection of 51 
new MPM marker candidates.  52 
 53 
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3 
1. Introduction 59 
Malignant pleural mesothelioma (MPM) is an aggressive disease mainly caused by 60 
asbestos exposure [1]. The diagnosis requires immunohistochemistry (IHC), 61 
combining panels of antibodies against MPM markers (positive for MPM) like 62 
calretinin, podoplanin (clone D2-40), cytokeratins 5/6 or WT-1 together with 63 
carcinoma-markers (negative for MPM) like epithelial cell adhesion molecule (Ep-64 
CAM, clone Ber-EP4), carcinoembryonic antigen (CEA) or thyroid transcription 65 
factor-1 (TTF-1). However, the discrimination of MPM from other malignancies 66 
affecting the lung can be difficult. Particularly, the distinction between MPM and 67 
lung adenocarcinoma (ADCA) is most challenging [3]. Recently, antibody-68 
independent approaches have evolved as alternative tools for the discrimination of the 69 
two diseases, based on gene expression-ratios, RT-PCR or DNA-methylation profiles 70 
[4-7]. Despite promising laboratory-based results, the translation of similar techniques 71 
into clinical routine remains problematic [8-10].  72 
Here, we propose a combined proteomic and transcriptomic strategy for the 73 
identification and selection of new protein-markers for the discrimination between 74 
MPM and ADCA. First, we applied the recently developed mass-spectrometry (MS) 75 
based cell surface capturing (CSC) technology [11] towards the discovery of the N-76 
glycosylated surfaceome of MPM and ADCA cells. Thereafter, we used the higher 77 
throughput Low Density Microarray (LDA) technique, to assess MPM specificity of 78 
selected N-glycoproteins on a larger panel of MPM and ADCA cell lines. Our 79 
approach revealed thy-1/CD90 (THY1) and teneurin-2 (ODZ2) as new MPM marker 80 
candidates. Using a commercially available antibody, we verified thy-1/CD90 81 
expression in tumor samples by IHC, showing that results from our proteo-82 
transcriptomic approach can potentially be directly translated into diagnostic routine.  83 
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2.    Materials and Methods 84 
2.1. Cell culture 85 
Primary MPM cell cultures were derived from tumor specimens obtained at the time 86 
of surgery from patients at the University Hospital Zürich with a confirmed diagnosis, 87 
or were derived from MPM malignant pleural-effusions, as previously described [12]. 88 
The study was approved by the Ethics Committee of the University Hospital Zürich 89 
and written informed consent was obtained from all patients. Primary tumor cultures 90 
were characterized by immunodetection of the MPM markers mesothelin, calretinin, 91 
wt-1, podoplanin (clone D2-40), N-cadherin and vimentin. MPM cell lines MSTO-92 
211H, H2052, H2452 and H226 were from American Type Culture Collection ATCC 93 
(Manassas, VA), ZL55 was established in our laboratory [13]. MPM cells were 94 
cultured as described before [12]. The ADCA cell lines Calu-3, A549, Calu-6, SK-95 
LU-1 and the adeno-squamous lung cancer cell line H596 were from ATCC, ZL25 96 
was established in our laboratory [14]. ADCA cells were cultured in RPMI-1640 97 
(Gibco/Invitrogen) with 10% FCS, 2 mM L-glutamine, 1% (w/v) 98 
penicillin/streptomycin. All cell lines were maintained at 37°C in a humidified 99 
atmosphere with 5% CO2. 100 
2.2. Cell Surface Capturing (CSC) and mass-spectrometric analysis 101 
SILAC labelling, CSC and mass spectrometric analysis of the MPM cell line ZL55 102 
and the ADCA cell line Calu-3 were performed as previously described [11] [15]. 103 
Heavy-Lysine and heavy-Arginine (L-Lysine-
13
C6,
15
N2 and L-Arginine-
13
C6,
15
N4, 104 
Sigma) were used according to the manufacturer’s instructions. All MS/MS spectra 105 
were converted to mzXML and searched against the UniProt database (Version 57.15) 106 
  
 
 
 
 
 
5 
using the SEQUEST algorithm. Statistical data-analysis was performed using a 107 
combination of ISB (Institute of Systems Biology, Seattle) open-source software tools 108 
(PeptideProphet
TM
, ProteinProphet
TM
, TPP version 4.3.1; 109 
http://tools.proteomecenter.org/software.php). A ProteinProphet protein probability 110 
score of at least 0.9 was used for data-filtering, followed by manual validation. 111 
Quantitative SILAC data analysis was performed using the XPRESS software [16, 112 
17]. Data was imported, stored, annotated and validated within the in-house developed 113 
SISYPHUS database software. 114 
2.3. Low Density Arrays (LDAs ) 115 
Cell lines were grown to ~80% confluence in 25 cm
2
 flasks, and total RNA was 116 
isolated using the RiboPure kit (Ambion, Austin, TX) as indicated by the 117 
manufacturer. RNAs were recovered in 50 l elution buffer and concentrations 118 
determined by spectrophotometric measurement in a NanoDrop ND-1000 (Thermo 119 
Scientific, Wilmington, DE) device. For synthesis of cDNA, 750 ng total RNA were 120 
reverse-transcribed using the High-Capacity cDNA Reverse-Transcription kit 121 
(Applied Biosystems, Foster City, CA) in a total volume of 30 l, following the 122 
manufacturer’s instructions. This amount had been experimentally determined to 123 
warrant synthesis of cDNA and subsequent amplification by real-time PCR under 124 
non-saturated, linear conditions. The quality of cDNA was verified by PCR 125 
amplification of a 2-microglobulin fragment in 50 l reactions containing 2 l 126 
cDNA, 1x Buffer II (Applied Biosystems), 1.5 mM MgCl2, 0.13 M each primer, 0.2 127 
mM each dATP, dTTP, dCTP, and dGTP, and 1.25 units AmpliTaq Gold (Applied 128 
Biosystems). Amplification conditions were: 1 cycle at 95ºC for 6 min, 35 cycles at 129 
95ºC for 45 seconds, 60ºC for 1 min, and 72ºC for 30 sec, followed by one final cycle 130 
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at 72ºC for 10 min. Primer sequences were: 2-F, 5’-131 
GTGGAGCATTCAGACTTGTCTTTCAGC-3’, and 2-R, 5’-132 
TTCATCCAATCCAAATGCGGCATCTTC-3´. PCR products were visualized by 133 
electrophoresis on polyacrylamide gels. Low Density Arrays for analysis of 22 genes 134 
(three internal controls) were obtained from Applied Biosystems. Each LDA slot was 135 
loaded with 100 l solution containing 1x Universal Master Mix (Applied 136 
Biosystems) and 10 l cDNA. PCR amplification was performed in a 7900HT Fast 137 
Real-Time PCR System (Applied Biosystems) apparatus using following cycle 138 
conditions: 1 cycle of 50ºC for 2 min, 1 cycle of 94ºC for 10 min, and 40 cycles of  139 
97ºC for 30 sec, 60ºC for 1 min. Relative gene expression was calculated by using the 140 
2
– Ct   
method [18]. For each sample, three technical replicates were measured and 141 
averaged before performing calculation. 18s and GAPDH were used as internal 142 
references. 143 
2.4. Western blot  144 
Detection of mesothelin and N-cadherin was performed on the MPM cell line ZL55 145 
and the ADCA cell line Calu-3 by Western blot as previously described [12]. 146 
Detection of thy-1/CD90 was performed without reducing agents on RIPA-buffer 147 
(Upstate Biotech-Millipore, Lake Placid, NY) lysates of the MPM cell lines ZL55 and 148 
SDM5, and the ADCA cell lines Calu-3 and SK-LU-1, using a monoclonal anti-thy-1 149 
antibody (clone AS02, - Dianova, Hamburg, Germany) at 1:5000 dilution [19]. For 150 
sample deglycosylation, cell lysates were incubated overnight with 5 U/mg PNGaseF 151 
(Roche, Basel, Switzerland) at 37ºC. 152 
2.5. Immunofluorescent staining. 153 
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Immunofluorescent staining was performed on the ZL55 MPM cells and the Calu-3 154 
ADCA cells after fixation with 4% paraformaldehyde and permeabilization with 0.1% 155 
TritonX-100 on uncoated coverslips. Antibody clone 5E10 (BD-Pharmingen, San 156 
Diego, CA) was used at 1:100 dilution for thy-1/CD90 detection. Mouse IgG1κ at 157 
1:100 (BD-Pharmingen) was used as specificity isotype-control. Cells were 158 
counterstained with Alexa Fluor-488-conjugated cholera-toxin (Invitrogen) at 1:5000 159 
dilution and DAPI (Sigma-Aldrich) at 1:1000 dilution. Images were acquired by 160 
confocal laser-scanning microscopy on a TCS-SPE microscope (Leica Microsystems, 161 
Wetzlar, Germany) at 63x magnification and processed (brightness and contrast 162 
adjustments and necessary cropping) using the Java-based program ImageJ (National 163 
Institute of Health, http://rsb.info.nih.gov/ij/). 164 
2.6. Tissue samples and immunohistochemistry 165 
Fresh frozen human tumor specimens were obtained from the Biobank at the Institute 166 
for Surgical Pathology, University Hospital Zürich. Corresponding formalin-fixed, 167 
paraffin-embedded tumor tissues were processed and diagnoses reported according to 168 
the guidelines of the Swiss Society of Pathology. Immunohistochemistry was 169 
performed on ice-cold, acetone fixed, frozen whole sections of 5 μm thickness after 170 
endogenous peroxidase quenching. Thy-1/CD90 detection was performed using the 171 
antibody-clone 5E10 (BD-Pharmingen) at 1:20 dilution and the Vectastain Elite ABC 172 
Universal Kit (Vector Laboratories) according to the manufacturer’s instructions. 173 
Immunoreactivity was visualized by incubation with 3,3’-diaminobenzidine 174 
tetrahydrochloride (Vector Laboratories) followed by counterstaining with 175 
haematoxylin QS (Vector laboratories). Mouse IgG1κ (BD-Pharmingen) at 1:20 was 176 
  
 
 
 
 
 
8 
used as specificity isotype-control. For each sample, stroma staining-intensity was 177 
used as internal reference.  178 
3. Results 179 
3.1. SILAC-based CSC proteomic analysis of N-glycosylated surface proteins 180 
In order to identify differences in-between the surfaceomes of MPM and ADCA we 181 
used a SILAC-based CSC proteomic strategy (Fig. 1). The MPM cell line ZL55 and 182 
the ADCA cell line Calu-3 were grown in media containing heavy or light isotope 183 
forms of the aminoacids arginine and lysine, respectively (SILAC protocol) [20]. The 184 
incorporation of different aminoacid isotopes allows to mix the two cell types in equal 185 
amounts before lysis and to process them together. MS discrimination between MPM-186 
derived proteins (containing heavy forms of arginine and lysine) and ADCA proteins 187 
(containing light forms of arginine and lysine) is then possible based on the mass 188 
differences of the incorporated heavy and light peptide isoforms. Following the CSC 189 
protocol, the sugar moieties of the cell surface exposed glycoproteins are labelled 190 
with biotin hydrazide on the living cells and, after protein digestion with trypsin, the 191 
glycopeptides are enriched with streptavidin coated beads. Using the enzyme 192 
PNGaseF, N-glycosylated peptides are then specifically released and analyzed via 193 
microfluidic LC-MS/MS. Overall, 100 cell surface N-glycoproteins, including 37 CD 194 
annotated proteins, were identified (Supplementary Table ST1). The MS analysis also 195 
revealed 211 MPM/ADCA N-glycopeptides containing a deamidation signature 196 
within the NXS/T motif, indicating the specific isolation and PNGaseF-mediated 197 
release of those N-glycopeptides via CSC (Supplementary Table ST2). We thereafter 198 
used the software XPRESS to calculate abundance ratios between the MPM and 199 
ADCA proteins. Among the glycoproteins upregulated in MPM, we identified the 200 
  
 
 
 
 
 
9 
known MPM markers mesothelin (UniProt ID MSLN_human, Q13421; Entrez gene 201 
name MSLN) and N-cadherin (synonyms CD325, Cadherin-2; UniProt ID 202 
CADH2_human, P19022; Entrez gene name CDH2) (Fig. 2A) The clear upregulation 203 
of the two proteins detected by MS in ZL55 (mesothelin abundance-ratio calculated 204 
with the software XPRESS revealed a ratio of ADCA over MPM of 0.04 ± 0.00 and 205 
for N-cadherin an abundance-ratio of 0.05 ± 0.04) matched the results obtained by 206 
Western blot (WB) (Fig. 2B), confirming the specificity of our approach.  207 
3.2. Semi-quantitative RT-PCR cell lines screening for MPM cell surface 208 
glycoprotein-marker candidates  209 
In the next set of experiments, we used LDAs in order to further qualify the initial 210 
MPM glycoprotein markers at the transcription level on a larger panel of 211 
representative and diverse MPM and ADCA cell lines (Table 1). The mRNA 212 
expression of 19 pre-qualified N-glycoproteins from the proteomic screen, including 213 
mesothelin and N-cadherin as landmark proteins, was analyzed in fifteen MPM and 214 
six ADCA cell lines (Fig. 3 and supplementary table ST3). Mesothelin transcript was 215 
expressed in ten out of fifteen (67%) MPM cell lines and in the adeno-squamous cell 216 
line H596. N-cadherin was expressed in all (100%) MPM and also in three (50%) 217 
ADCA cell lines. Among the other investigated genes, thy-1/CD90 (synonym CD90; 218 
UniProt ID THY1_human, P04216; Entrez gene name THY1) and teneurin-2 219 
(UniProt ID TEN2_human, Q9NT68; Entrez gene name ODZ2) displayed a selective 220 
association with MPM (Fig. 3A and B). Thy-1/CD90 (THY1) showed homogenous 221 
mRNA expression in MPM and was absent from ADCA cell lines. Teneurin-2 222 
(ODZ2) was expressed in eleven MPM cell lines, but only at low levels in one ADCA 223 
(SK-LU-1) and one adeno-squamous cell line (H596). All other candidates presented 224 
  
 
 
 
 
 
10 
a heterogeneous expression profile without individual discriminatory power between 225 
MPM and ADCA.  226 
3.3. Western blot verification of thy-1 in MPM and ADCA cell lines  227 
As a first step to verify our markers by immunologic assays, we tried to acquire 228 
suitable antibodies. Since no antibody for human teneurin-2 was commercially 229 
available, we generated a rabbit anti-serum against two extracellular peptides 230 
identified in the proteomic screens from teneurin-2. However, no specific signals 231 
could be detected in WB and IHC experiments (data not shown). For thy-1/CD90, we 232 
tested a series of commercially available antibodies (data not shown) and selected the 233 
mouse clone AS02 to compare thy-1/CD90 expression in two MPM (ZL55, SDM5) 234 
and two ADCA (Calu-3, SK-LU-1) cell lines by WB (Fig. 4). Chemoluminescent 235 
signals of the appropriate molecular weight were obtained for deglycosylated thy-236 
1/CD90 in MPM cells (lane 6 and 8), but not in ADCA cells (lane 2 and 4). Only in 237 
the MPM SDM5 cell line, thy-1/CD90 protein was also recognized in its 238 
glycosylated, higher molecular weight form (lane 7). 239 
3.4. Immunohistochemical verification of thy-1 in human tissues  240 
We further set out to validate our proteo-transcriptomic approach in IHC assays. In 241 
our hands, the anti-thy-1 clone AS02 did not perform satisfactory on tissues (data not 242 
shown), thus, we tested additional commercially available antibodies and selected the 243 
clone 5E10. It has to be mentioned that none of the tested antibodies did perform on 244 
formalin-fixed paraffin-embedded (FFPE) tissues (data not shown). In agreement with 245 
MS, RT-PCR and WB results, using clone 5E10, thy-1/CD90 expression was detected 246 
in MPM, but not in ADCA cell lines (Fig. 5A). The overlay of a cholera-toxin 247 
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staining for the plasma membrane associated ganglioside GM1 with anti-thy-1 248 
staining suggests a co-localisation of both molecules at the cell surface. We further 249 
used clone 5E10 to investigate human frozen sections from four epithelioid and two 250 
biphasic MPM tumors as well as eight ADCA with different grading levels (Fig. 5B, 251 
supplementary table ST4). Reaction to anti-thy-1 antibody was observed in the tumor-252 
stromal cells of both tumor types. Three MPM cases presented discrete numbers of 253 
tumor cells with moderate membrane staining whereas ADCA cells reacted only 254 
modestly, if at all, to anti-thy-1 with weak to moderate cytoplasmic staining of tumors 255 
cells toward the stroma.  256 
4. Discussion 257 
In our work we investigated a new approach to the analysis of the MPM surfaceome 258 
toward the identification of markers for the discrimination of MPM from ADCA. To 259 
do so, we analyzed the surfaceomes of two MPM and ADCA cell lines via the CSC 260 
technology. The CSC technology enables the parallel identification of surface 261 
exposed N-glycosylated proteins using antibody-independent mass spectrometric 262 
techniques. The CSC technology thus allows for large screens of proteins without 263 
biases related to antibody availability or quality. To sort for N-glycoproteins 264 
associated with MPM, we combined the CSC with the SILAC strategy for relative 265 
protein quantitation and selected those proteins showing upregulation in MPM 266 
compared to ADCA. The validity of this approach was corroborated by the unbiased 267 
detection of the glycoproteins mesothelin and N-cadherin among the proteins with 268 
higher abundance in MPM. Both proteins are in fact known to be associated with 269 
MPM, even if their specificity is unsatisfactory for clinical application [21-23]. In 270 
addition, MS observed overregulation of the two proteins in MPM could be 271 
  
 
 
 
 
 
12 
reproduced and confirmed by antibody-assays (WB). However, it should be 272 
mentioned that we could not observe the widely accepted MPM markers calretinin, 273 
podoplanin, cytokeratins 5/6 or WT-1. This was due to the fact that these protein-274 
markers are neither cell surface exposed (with the exception of podoplanin) nor N-275 
glycosylated, and thus not accessible by our approach. 276 
Among the N-glycoproteins upregulated in MPM, we focused on those 277 
proteins, which were only rarely or not at all reported in the literature in association 278 
with MPM before. In order to anticipate the MPM specificity and sensitivity of these 279 
selected proteins, we screened fifteen MPM and six ADCA cell lines by LDAs assays. 280 
We decided to apply LDAs, owing to the fact that RT-PCR protocols are nowadays 281 
standardized, quick, easily accessible and relatively cheap compared to current 282 
proteomic approaches. In contrast to screens based solely on mRNA investigations, 283 
here we could take advantage of our previous MS analysis, selecting only for genes 284 
known to be translated in proteins. Again, to confirm the validity of the approach, we 285 
first looked at our landmarks proteins mesothelin and N-cadherin. As expected, none 286 
of the two proteins resulted to be a reliable single discriminator for MPM [21-23]. 287 
Among the other investigated genes, thy-1/CD90 (THY1) and teneurin-2 (ODZ2) 288 
showed the strongest association with MPM. Teneurin-2 (ODZ2) is one of the four 289 
members of the teneurin family of proteins. These more than 300 kDa large 290 
transmembrane proteins are probably involved in cell-signalling and transcription 291 
regulation, but their function is yet unknown [24]. Only few studies report about 292 
teneurin-2 in cancer and there is some uncertainty about its potential tumor-293 
suppressor or oncogenic function [25, 26]. Since no commercial antibodies against 294 
human teneurin-2 were available, we produced rabbit-antisera against two 295 
extracellular peptide sequences. However, reaction of the antibody was 296 
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unsatisfactory. Thy-1/ CD90 (THY1) is a small, heavily glycosylated GPI-anchored 297 
cell surface protein with the highest expression in human among (primarily fetal) 298 
thymic stromal cells and most fibroblasts [27]. A tumor-suppressor function of thy-299 
1/CD90 has been proposed in ovarian and nasopharyngeal cancer [28-32], but protein 300 
expression in cancer stem-cells has rather been associated with more aggressive 301 
behaviour and chemoresistance [33-35]. Recently, thy-1/CD90 has been observed in 302 
four MPM cell cultures grown in low serum conditions and a correlation to highly-303 
proliferative or stem-cell-like cells was speculated by the authors [36].  304 
We used WB to validate MPM specificity of thy-1/CD90 at protein level. 305 
Interestingly, in one MPM case (cell line ZL55), thy-1/CD90 was detectable only 306 
after deglycosylation with PNGaseF, pointing out a clear pitfall of approaches based 307 
solely on antibodies. Finally, we verified thy-1/CD90 expression in MPM and ADCA 308 
tissues by IHC on frozen sections. Three MPM patients presented discrete numbers of 309 
tumor cells reacting positively to anti-thy-1 antibody (clone 5E10), while ADCA 310 
tumor cells reacted rather weakly and unspecific to the antibody. However, both 311 
tumors showed positive reaction of the tumor-stromal cells. To further verify and 312 
confirm these preliminary observations in larger scale, suitable antibodies for 313 
paraffin-embedded tissues would be essential.  314 
5. Conclusions 315 
Our work investigated a novel proteo-transcriptomic strategy for the identification of 316 
MPM biomarkers discriminatory from ADCA. Cell surface analysis with the CSC 317 
technology in combination with LDAs enabled the high-throughput and multiplexed 318 
screen required for the investigation and pre-clinical selection of new biomarkers. 319 
This strategy resulted to be a valid complement to approaches based solely on 320 
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antibodies, whose limitations are often related to epitope and application-based 321 
constraints. Our results provide evidence that teneurin-2, and especially thy-1/CD90, 322 
are cell surface accessible marker candidates for the differentiation of MPM from 323 
ADCA. 324 
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Legends for figures 478 
Figure 1. Workflow for the identification and verification of MPM discriminatory 479 
marker candidates. Cell surface capturing (CSC) was applied in combination with 480 
SILAC for quantitative analysis of the N-glycosylated cell surface proteins of the 481 
MPM cell line ZL55 and the ADCA cell line Calu-3. Differentially regulated proteins 482 
were investigated by LDA assays on a panel of MPM and ADCA cell lines. Proteins 483 
showing potential specificity for MPM were verified at cell and tissue level by 484 
antibody-based assays.  485 
Figure 2. Detection and quantitation of the reference mesothelioma markers            486 
mesothelin and N-cadherin. A, Mass spectrometric quantitation of the mesothelin 487 
peptide LAFQNMNGSEYFVK and N-cadherin peptide VDIIVANLTVTDK 488 
identified by CSC in the SILAC-heavy-labelled MPM cell line ZL55 and the light-489 
labelled ADCA cell line Calu-3. The XPRESS software was used to define the elution 490 
areas of the peptides and calculate the isotopic ratios between light and heavy peptide 491 
forms. Elution areas used for quantitation are delimited by the dotted blue curves 492 
between the dashed black-lines. The red traces are the peptide chromatograms 493 
identified in the elution areas used for quantitation. B, Western blot detection of 494 
mesothelin and N-cadherin. Reaction against the anti-mesothelin antibody can be 495 
detected for the MPM cell line ZL55, but is only weak or absent for the ADCA cell 496 
line Calu-3. Similar can be observed using the anti-N-cadherin antibody.  497 
Figure 3. Mass spectrometric quantitation of the proteins thy-1/CD90 and teneurin-2 498 
and relative mRNA expression as assessed by low density array RT-PCR profiling. A, 499 
Elution profiles of the thy-1/CD90 peptide SPPISSQNVTVLR and the teneurin-2 500 
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peptide NSSIDSGEAEVGR identified by CSC of the heavy-labeled MPM cell line 501 
ZL55 and the light-labeled ADCA cell line Calu-3. Quantitation was calculated with 502 
the software XPRESS and derived from the isotopic ratios of the elution areas of the 503 
peptides. Dotted blue curves between the dashed black-lines mark elution areas used 504 
for relative quantiation. The red traces correspond to the peptide chromatograms 505 
identified in the elution areas used for quantitation. B, Graphs show the relative 506 
mRNA levels of mesothelin (gene name MSLN), N-cadherin (gene name CDH2), 507 
thy-1/CD90 (gene name THY1) and teneurin-2 (gene name ODZ2) in fifteen MPM 508 
(dashed bars, cell lines ZL55 to SDM61) and six ADCA (black bars, cell lines Calu-3 509 
to SK-LU-1) cell lines.  510 
Figure 4. Expression of thy-1/CD90 protein in MPM and ADCA cell lines. Protein 511 
lysates from ADCA cell lines Calu-3 and SK-LU-1 and from MPM cell lines ZL55 512 
and SDM5 were separated on SDS-PAGE (4-12%). For deglycosylation, cell lysates 513 
were treated with PNGaseF. Using mouse anti-thy-1 antibody, a band compatible with 514 
the size of thy-1/CD90 (28 kDa) was detected in the untreated SDM5 lysates. Upon 515 
PNGaseF treatement, signals at 17 kDa were detected in both MPM cell lines, which 516 
agree with the weight of deglycosylated thy-1/CD90. Independent of PNGaseF 517 
treatement, no signal could be detected for the ADCA cell lines. The position of 518 
weight standards is indicated at the left, while - and + indicate lysates without and 519 
with PNGaseF treatement, respectively. 520 
Figure 5. Immunofluorescent and immunohistochemical detection of thy-1/CD90.                           521 
A, Immunofluorescent staining of thy-1/CD90 protein in MPM and ADCA cell lines. 522 
The MPM cell line ZL55 and the ADCA cell line Calu-3 were stained with mouse 523 
anti-thy-1 antibody 5E10 (red). Cell membranes were counterstained with Alexa 524 
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Fluor 488-conjugated cholera-toxin (green), and nuclei with DAPI (blue). Merged 525 
images are shown at the far right. B, Two representative IHC examples of human 526 
MPM (a-b) and ADCA (c-d). Images were recorded at 10x and representative regions 527 
(insets) at 20x magnification. Reference slides from the same tumors were also 528 
stained with haematoxylin-eosin.  529 
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Table 1: Cell lines used for LDAs assays 550 
Cell line Type Histology Origin 
Patient 
(sex/age) 
Source/Reference 
ZL55 MPM Epithelioid Tumor M/52 Our lab, ref.13 
SDM5 MPM Epithelioid Effusion M/54 Our lab 
SDM13 MPM Epithelioid Tumor M/58 Our lab 
SDM16 MPM Epithelioid Tumor M/65 Our lab 
SDM22 MPM Epithelioid Effusion M/62 Our lab 
SDM46 MPM Epithelioid Tumor M/57 Our lab 
SDM47 MPM Epithelioid Tumor M/58 Our lab 
SDM48 MPM Epithelioid Tumor M/55 Our lab 
SDM55 MPM Epithelioid Tumor M/40 Our lab 
SDM57 MPM Epithelioid Tumor F/62 Our lab 
SDM61 MPM Epithelioid Tumor M/66 Our lab 
MSTO-211H MPM Biphasic Effusion M/62 Our lab 
H2052 MPM Sarcomatoid Effusion M/65 ATCC 
H2452 MPM Epithelioid Tumor M/- ATCC 
H226 MPM Epithelioid Effusion M/- ATCC 
Calu-3 NSCLC ADCA Effusion M/25 ATCC 
Calu-6 NSCLC ADCA - F/61 ATCC 
A549 NSCLC ADCA - M/58 ATCC 
SK-LU-1 NSCLC ADCA - F/60 ATCC 
ZL25 NSCLC ADCA - M/60 Our lab, ref.14 
H596 NSCLC Adenosquamous - M/73 ATCC 
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